Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared with Heparin and Planned Glycoprotein IIb/IIIa Blockade during Percutaneous Coronary intervention: REPLACE-2 Randomized Trial

JAMA

Volumn 289, Issue 7, 2003, Pages 853-863

  Lincoff, A Michael ^a   Bittl, John A ^b   Harrington, Robert A ^c   Feit, Frederick ^d   Kleiman, Neal S ^e   Jackman, J Daniel ^t   Sarembock, Ian J ^f   Cohen, David J ^g   Spriggs, Douglas ^h   Ebrahimi, Ramin ⁱ   Keren, Gadi ^j   Carr, Jeffrey ^k   Cohen, Eric A ^l   Betriu, Amadeo ^m   Desmet, Walter ⁿ   Kereiakes, Dean J ^o   Rutsch, Wolfgang ^p   Wilcox, Robert G ^q   De Feyter, Pim J ^r   Vahanian, Alec ^s   Topol, Eric J ^a   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b Munroe Regional Med Center   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h Clearwater Cardiovascular Consultants   (United States)

ⁱ VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^j TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^k EAST TEXAS MEDICAL CENTER   (United States)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o The Carl & Edyth Lindner Center for Research & Education   (United States)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^r ERASMUS MEDICAL CENTER   (Netherlands)

^s BICHAT HOSPITAL   (France)

^t Hopital Bichat ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; TREATMENT OUTCOME; AGED; ATHERECTOMY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; ISCHEMIA; MIDDLE AGED; PEROPERATIVE COMPLICATION; STENT; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ATHERECTOMY, CORONARY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTRAOPERATIVE COMPLICATIONS; ISCHEMIA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037453968     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.7.853     Document Type: Article

References (37)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest. 1990;86:385-391.
2. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi: role of platelet factor 4. Circulation. 1994; 89:1523-1529.
3. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998; 97:251-256.
4. Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vasc Surg. 2001;33:587-594.
5. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa blockade in coronary artery disease. J Am Coll Cardiol. 2000;35:1103-1115.
6. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
7. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ, for the Bivalirudin Angioplasty Study Investigators. Bivalirudin vs heparin during coronary angioplasty for unstable or post-infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001; 142:952-959.
8. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847-853.
9. Lincoff AM, Bittl JA, Kleiman NS, et al. The REPLACE 1 Trial: a pilot study of bivalirudin vs heparin during percutaneous coronary intervention with stenting and Gp IIb/IIIa blockade [abstract]. J Am Coll Cardiol. 2002; 39:16A.
10. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial, Phase 1: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
11. Landefeld LS, Cook EF, Hatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987; 82:703-713.
12. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
13. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
14. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug Inf J. 2001;35:435-449.
15. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
16. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments, I: ethical and scientific issues. Ann Intern Med. 2000;133:455-475.
17. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, et al. Defining the optimal activated clotting time during percutaneous coronary intervention. Circulation. 2001;103:961-966.
18. Topol EJ, Mark DB, Lincoff AM, et al. Enhanced survival with platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: one year outcomes and health care economic implications from a multicenter, randomized trial. Lancet. 1999;354:2019-2024.
19. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1-6.
20. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-2065.
21. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
22. EPILOG Investigators. Platelet glycoprotein IIb/ IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
23. Berkowitz S, Sane D, Sigmon K, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol. 1998;32: 311-319.
24. Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab glycoprotein IIb/IIIa blockade. Am Heart J. 2000; 140:74-80.
25. Cohen H, ed. Redbook Drug Topics 2002. Montvale, NJ: Thomson Medical Economics; 2002.
26. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90: 1522-1536.
27. Weitz JI, Bates SM. Acute coronary syndromes: a focus on thrombin. J Invasive Cardiol. 2002;14:2B-7B.
28. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36-39.
29. US Food and Drug Administration. Medical-statistical review for xeloda [NDA No. 20-896]; 2001. Available at: http://www.fda.gov/cder/foi/nda/2001 /20-896S010_Xeloda_medr_P1.pdf. Accessed January 15, 2003.
30. INJECT Investigators. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995;346:329-336.
31. Rothmann M, Li N, Chen G, Chi GYH, Temple R, Tsou H-H. Design and analysis of non-inferiority mortality trials in oncology. Stat Med. In press.
32. Siegel JP. Equivalence and noninferiority trials. Am Heart J. 2000;139:S166-S170.
33. Koerber JM, Mattson JC, Smythe MA, Gauss IA, Wright JA. A comparison of the Hemoch ron 401 and the Hemochron Jr Signature in cardiac catheterization and interventional patients [online only abstract]. J Thrombosis Haemostasis. 2001;86(suppl). Available at: http://www.cartesian-secure.com /isth2001/iAbstract/html/absP1589.html. Accessed January 15, 2003.
34. Topol EJ, Ferguson JJ, Weisman HF, et al, for the EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
35. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained supression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial. Circulation. 1999;99:1951-1958.
36. Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002;288:2130-2135.
37. Kereiakes DJ, Lincoff AM, Anderson KM, et al. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 2002;90:628-630.